Regorafenib in Chinese patients with metastatic colorectal cancer: Subgroup analysis of the phase 3 CONCUR trial

BACKGROUND AND AIM: In the phase 3 CONCUR trial (NCT01584830), regorafenib improved overall survival (OS) versus placebo in Asian patients with treatment‐refractory metastatic colorectal cancer (mCRC). We conducted a post hoc subgroup analysis of Chinese patients in CONCUR. METHODS: Adults with mCRC...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Jianming, Xu, Rui‐Hua, Qin, Shukui, Pan, Hongming, Bai, Yuxian, Chi, Yihebali, Wang, Liwei, Bi, Feng, Cheng, Ying, Liu, Tianshu, Ma, Dong, Shen, Lin, Ba, Yi, Liang, Jun, Wang, Xin, Yau, Thomas C C, Ma, Brigette B, Yeh, Kun‐Huei, Lin, Jen‐Kou, Kappeler, Christian, Shapiro, JoAnn, Kalmus, Joachim, Li, Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Clinical Gastroenterology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497105/
https://www.ncbi.nlm.nih.gov/pubmed/31900959
http://dx.doi.org/10.1111/jgh.14974

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497105/
https://www.ncbi.nlm.nih.gov/pubmed/31900959
http://dx.doi.org/10.1111/jgh.14974

Ejemplares similares